Biota Pharmaceuticals (NASDAQ:BOTA) was downgraded by stock...

Biota Pharmaceuticals (NASDAQ:BOTA) was downgraded by stock analysts at ING Group from a “hold” rating to a “sell” rating in a report issued on Thursday.

The analysts wrote, “Biota Pharmaceuticals (BOTA) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself.”

Biota Pharmaceuticals (NASDAQ:BOTA) traded down 0.90% during mid-day trading on Thursday, hitting $2.765. 33,293 shares of the company’s stock traded hands. Biota Pharmaceuticals has a 52-week low of $2.75 and a 52-week high of $7.07. The stock’s 50-day moving average is $4.05 and its 200-day moving average is $4.82. The company’s market cap is $97.0 million.

Biota Pharmaceuticals (NASDAQ:BOTA) last announced its earnings results on Tuesday, May 6th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.28) by $0.37. On average, analysts predict that Biota Pharmaceuticals will post $-0.22 earnings per share for the current fiscal year.

Biota Pharmaceuticals, Inc, formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza.